Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

The tumor microenvironment (TME) consists of mediators surrounding a tumor, including diverse cell types, blood vessels, and other cellular components. Certain elements of the TME can benefit patients ...

MILAN — Is chronic lymphocytic leukemia (CLL) progression primarily driven by genetic mutations or by external cues from the tumor microenvironment? Despite major strides in targeted therapies, CLL ...

T cells dynamically adapt to signals in the TME, transitioning between effector, exhausted, and regulatory states. Cellular interactions, metabolic stress, and physical barriers (e.g., ECM) shape ...

The tumor microenvironment is not just a site of cancer growth—it is a high-stakes metabolic contest where tumor and immune cells vie for limited resources. Amino acids, once seen as passive nutrients ...

No tumor is an island. In the past two decades, it’s become increasingly appreciated that cancers are dependent on neighboring cells for their growth and survival. These tumor-friendly communities—or ...

Over the past decade, the advent of immune checkpoint blockade (ICB) therapy has transformed cancer treatment. Unlike conventional cytotoxic and targeted therapies, immunotherapy leverages both the ...

Cancer cells and tumors do not exist in a vacuum. Far from the isolation and self-sufficiency of the fictional Wakanda, tumors develop in and alter the nearby milieu of immune cells, connective tissue ...